JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37

Immunovant, Inc. (NASDAQ:IMVT) is one of the best biotech stocks with high potential. On September 30, JPMorgan analyst Brian Cheng lowered the firm’s price target on Immunovant, Inc. (NASDAQ:IMVT) to $33 from $37 while keeping an Overweight rating on the shares. Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? Immunovant, Inc. (NASDAQ:IMVT) reported that its cash and cash equivalents totaled approximately $598.9 million in the quarter ending June 30, 2025, providing runway ...